Fexuprazan to Prevent Stomach Bleeding in Heart Patients on Dual Antiplatelet Therapy
Compares fexuprazan with lansoprazole to prevent upper digestive bleeding after a coronary stent.
Key facts
- Who runs it
- SUK MIN SEO
- Where
- Seoul, South KoreaSee the site
- Trial code
- NCT07479056
- KCT0009504
- Registry title
- Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 24 Oct 2024
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Fexuprazan 40mg
- Lansoprazole 30mg
- Record updated
- 19 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 20 or older who had a coronary stent placed and need dual antiplatelet therapy for 6 months or longer. They must also have a high risk of bleeding.
- Age
- 20 years or older
- Sex
- All sexes
- Disease stage
- Coronary artery disease treated with a coronary artery stent. Dual antiplatelet therapy is needed for 6 months or longer. At least 1 high bleeding risk factor, such as age 65 or older, low body weight, low hemoglobin, low platelets, severe kidney disease, long-term anticoagulant use, long-term NSAID or steroid use, heart failure, past stomach or duodenal ulcer, past gastrointestinal bleeding, or Helicobacter pylori infection.
- Earlier treatment
- A coronary artery stent must have been placed. Randomization takes place within 48 hours after stent implantation. People taking atazanavir, nelfinavir, or rilpivirine-containing drugs cannot join. People taking CYP 3A4 and P-GP inhibitors at the same time cannot join.
Main reasons for not taking part
- Allergy to the trial drug or benzimidazole-based drugs
- Severe anemia (hemoglobin below 8 g/dL) or blood transfusion within 4 weeks
- Active liver disease or AST or ALT more than three times the upper limit of normal
- eGFR below 30 or on dialysis
- Pregnant or breastfeeding women, or women planning to become pregnant
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- All four conditions below must be met; Patients who are 20 years of age or older, have undergone coronary artery stent implantation for coronary artery disease, and require dual antiplatelet therapy for 6 months or longer; Patients are considered to be at high bleeding risk if at least 1 criteria are met (Based on clinical recommendations (6,7,10,14-16) and expert consensus documents (17-19)) 1) Age ≥65 y 2) Low body weight (<55 Kg for men, <50 Kg for women) 3)Hemoglobin <11g/dL 4) Platelet count <100×109/L 5) Severe CKD: eGFR <30mL/min/1.73m2,5 or on hemodialysis 6) Anticipated use of long-term oral anticoagulation (warfarin or direct-acting oral anticoagulants) 7) Long-term use of oral NSAIDs or steroids 8) Heart failure 9) A history of previous gastric or duodenal ulcer. 10) A history of previous gastrointestinal bleeding. 11)Previous or confirmed Helicobacter pylori infection; A voluntary participant in this clinical trial who has provided written consent, or a legal guardian who has provided written consent on behalf of the participant; Those who agree to use a medically valid method of contraception* (including conditions in which pregnancy is medically impossible) during the clinical trial period Women who are medically unable to become pregnant can participate in this clinical trial: women who have undergone menopause (amenorrhea for more than 24 months), hysterectomy, salpingectomy, or bilateral oophorectomy, etc
- Medically valid contraceptive methods: intrauterine device (Loop, Mirena), physical barrier method (male condom, female condom (femidom)), subcutaneous contraception (Implanon, etc.), long-acting contraceptive injection, or tubectomy and ligation, vasectomy, etc. ( However, oral contraceptives cannot be used during this clinical trial, and it is recommended to use double contraception to prevent pregnancy while participating in this trial.)
Who cannot take part
- Patients taking drugs contraindicated for this clinical trial drug (e.g., patients taking atazanavir, nelfinavir, or rilpivirine-containing preparations)
- Concurrently taking CYP 3A4 and p-glycoprotein (P-GP) inhibitors
- Patients who have a hypersensitivity reaction to the components of this clinical trial drug or benzimidazole-based drugs or have a history of clinically significant hypersensitivity reaction
- Patients with contraindications to antiplatelet agents, such as allergies
- Genetic blood coagulation disorders
- Cases in which the investigator determines that the use of dual antiplatelet therapy is difficult due to severe liver cirrhosis, thrombocytopenia, or other medical conditions
- Hemodynamically unstable at the time of randomization (cardiogenic shock, uncontrolled arrhythmia, severe heart failure: NYHA Class IV)
- Patients with warning symptoms suspected of digestive malignancy (unintentional significant weight loss, recurrent vomiting, dysphagia, hematemesis, melena, etc.) within the past 3 months
- Patients with malignancy or serious illnesses with an expected survival of less than 1 year
- Dementia or individuals unable to understand the trial procedures or comply with the trial requirements
- Individuals with active infections, significant hematologic, renal, metabolic, gastrointestinal, endocrine disorders, or any other reason the investigator deems the subject unsuitable for participation in the clinical trial
- Severe anemia (hemoglobin < 8 g/dL) or blood transfusion within 4 weeks of randomization
- Active liver disease or impaired liver function (AST or ALT greater than three times the upper limit of normal)
- Advanced renal dysfunction: eGFR less than 30 mLmin/1.73m2 or patients receiving dialysis
- Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- Pregnant or breastfeeding women, or women planning to become pregnant
Where in South Korea
- The Catholic University of Korea, Eunpyeong St. Mary's HospitalSeoul, South KoreaContact: SUK MIN SEO, Assisted ProfessorTaking people
About the trial
What the trial wants to find out
This study evaluates whether fexuprazan is effective in preventing upper gastrointestinal bleeding and related upper gastrointestinal clinical events in high bleeding risk patients who require dual antiplatelet therapy after coronary stent implantation.
Read full original descriptionShow less
A total of 200 participants at a single center will be randomly assigned in a 1:1 ratio within 48 hours after stent implantation to receive either fexuprazan 40 milligrams or lansoprazole 30 milligrams once daily for 6 months. The study will compare upper gastrointestinal clinical events during follow-up
The 2 groups in the trial
- Fexuprazan group(P-CAB)Treatment being tested
Participants receive fexuprazan 40 mg once daily and lansoprazole placebo once daily.
Treatment: Fexuprazan 40mg
- Lansoprazole group(PPI)Existing treatment, for comparison
Participants receive lansoprazole 30 mg once daily and fexuprazan placebo once daily.
Treatment: Lansoprazole 30mg
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Active-Controlled Trial Evaluating Fexuprazan for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention-Fexuprazan for Patients With Dual Antiplatelet Therapy Trial
- Plain-language title
- Fexuprazan to Prevent Stomach Bleeding in Heart Patients on Dual Antiplatelet TherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 19 October 2026